Media

LEIDEN, NETHERLANDS June 25, 2025 Intellomx (Intelligent OMICS Ltd), a leading biotechnology company that applies artificial intelligence (AI) to accelerate drug discovery, today announced a follow-on target discovery collaboration with Johnson & Johnson*, to identify and evaluate novel biological targets for the treatment of lung cancer.

CAMBRIDGE, UNITED KINGDOM, April 28, 2025 Intellomx (Intelligent OMICS Ltd) today announced the deployment of Intellomx Pilot, delivering rapid identification of novel drugs arising from its existing precision therapeutic
target identification capability, offering pharmaceutical innovators a powerful tool to streamline and de-risk the drug discovery process.

London, UK – 18 April, 2025- Why has AI not delivered on its ambitious promise in drug discovery? This was the provocative opening posed by Professor Graham Ball during the AI Science Spotlight at BioTrinity in London last week—a question that cut to the heart of today’s drug discovery challenges

London, UK – 1 September, 2023 - Intelligent OMICS Ltd (Intellomx), a leading biotechnology company that applies artificial intelligence (AI) to accelerate drug discovery, today announced a target discovery collaboration with Janssen Research & Development, LLC (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to evaluate novel biological targets for the treatment of haematological cancers. The agreement was facilitated by Johnson & Johnson Innovation.

​NOTTINGHAM, UNITED KINGDOM, August 10, 2023 /EINPresswire.com/ --  Intelligent Omics Ltd (Intellomx) is
pleased to announce that it has joined Johnson & Johnson Innovation – JLABS, a premier life science incubator
program.

JLABS provides entrepreneurs with the lab space, resources and support needed to bring breakthrough healthcare solutions to patients around the world.